Follicle centre lymphoma follicular grade I II – III refractory – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 03 Jun 2026 04:03:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Follicle centre lymphoma follicular grade I II – III refractory – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-epcoritamab-with-rituximab-and-lenalidomide-for-patients-with-relapsed-or-refractory-follicular-lymphoma/ Wed, 29 Apr 2026 14:30:23 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-epcoritamab-with-rituximab-and-lenalidomide-for-patients-with-relapsed-or-refractory-follicular-lymphoma/ This clinical trial is focused on studying a type of cancer called relapsed or refractory follicular lymphoma. This is a condition where the cancer has either returned after treatment or has not responded to previous treatments. The study is testing a new treatment combination to see if it is safe and effective. The treatment being studied includes a new medication called Epcoritamab (GEN3013), which is a type of medicine known as a bispecific antibody. This is being tested in combination with two other medications, Rituximab and Lenalidomide, which are already used in treating this type of lymphoma.

The purpose of the study is to compare the effects of the combination of Epcoritamab with Rituximab and Lenalidomide against the effects of Rituximab and Lenalidomide alone. Participants in the study will receive either the new combination treatment or the existing treatment. The study will monitor how well the treatments work and how safe they are for the participants. The study will also look at how long participants live without the cancer getting worse, which is known as progression-free survival.

Participants will be involved in the study for a period of time, during which they will receive the treatments and have regular check-ups to monitor their health and the effects of the treatment. The study aims to provide more information about the potential benefits and risks of adding Epcoritamab to the existing treatment regimen for people with relapsed or refractory follicular lymphoma.

]]>